Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

nduct a Phase I/II clinical study of non-small cell lung cancer ("NSCLC") patients in parallel with a planned Phase I North American study in advanced solid tumor patients. Together, the two studies are expected to utilize open-label designs to evaluate the safety, tolerability and pharmacokinetic properties of multiple, ascending doses of L-DOS47 in tumor bearing patients. Helix anticipates the Polish study to additionally assess the prospective efficacy of L-DOS47 administration because of its focus on NSCLC patients. Helix also anticipates expanding the Polish study design to include arms in which patients will receive L-DOS47 administration together with leading chemotherapy or radiation therapy regimens. By doing so, Helix expects to broaden the likelihood of demonstrating efficacy in the study by additionally evaluating the envisioned chemo/radio-therapy potentiating properties of the DOS47 platform.

While the remaining clinic-enabling product development activities for L-DOS47 are progressing, Helix has continued to incur challenges in its manufacturing program which have in turn caused delays in the anticipated timing associated with filing its planned regulatory dossiers. After successfully completing production of GMP engineering batches of L-DOS47 earlier in the 2009 calendar year, the initial GMP clinical batch was rejected by the Company due to a deviation from the established manufacturing process, causing suspected contamination during fermentation. As a result, the Company has rescheduled production of its clinical batch, which has, in turn, caused program delays. Production of the required GMP clinical batch is now scheduled to be completed by the end of the Company's second quarter of fiscal 2010 to be followed by stability testing. Based on this, the Company now anticipates filing its U.S. Phase I and Polish Phase I/II regulatory dossiers by July 31, 2010, subject to timely and successful completion of the pre-IND filing requi
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... of Powers Lake, Wisconsin , ... a distribution and co-marketing agreement allowing ScriptPro to ... throughout the United States . ... management and workflow systems to retail and ambulatory ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
Breaking Medicine Technology:Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... Filtrona Porous Technologies, a custom developer and manufacturer ... to absorb, retain, transfer, filter or release fluids ... polyurethane foams and bonded fibers at the MEDICA ... 17 to 19 November 2010. ...
... Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics ... Moch, President and Chief Executive Officer, will present at ... Wednesday, November 17, 2010, 10:30 a.m. ET, at the ... Mr. Moch will give an update on the company,s ...
Cached Medicine Technology:Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:7/28/2014)... According to the Greek God Muscle Building Program review ... that teaches men how to completely transform their physique by ... its review that inside the Greek God Muscle Building Program ... gain the maximum muscle fiber recovery , ... gain , Ways to incorporate the specialization routines ...
(Date:7/28/2014)... 28, 2014 To commemorate World Hepatitis ... of Living with a Disability magazine has ... disorders that include hepatitis, gastrointestinal hemorrhage, inflammatory bowel disease, ... important new article highlights that, in the context of ... hepatitis and other disabling conditions related to the digestive ...
(Date:7/28/2014)... 28, 2014 Greta Pontarelli, 63, won her ... Champion title at the World Pole Sports Championships in London ... this athlete. She is the only U.S. competitor to qualify, ... Pole Sports Federation (IPSF). Over 150 athletes ranging in age ... in the competition. Pontarelli scored first place in the Masters ...
(Date:7/27/2014)... 28, 2014 Zensah®, the leader in compression ... include a wrist support . The wrist support features ... area. , Lateral and Medial Epicondylitis, more commonly referred to ... which there is inflammation of the tendons attached to the ... wrist pain, the muscles that work the wrist and fingers ...
(Date:7/27/2014)... regimens could provide shorter, more effective treatment options with ... with hepatitis C, even those most difficult to treat, ... The Lancet . , Both studies focused on ... genotype in the USA, Europe, North Asia, Australia, and ... treat. , Around 150 million people worldwide have chronic ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:Zensah® Releases New Wrist Support 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 5, 2009. In conjunction, the Company will host a conference call at ... update. , , Date: ... Conference call access:, Internet: www.istavision.com, ...
... KALAMAZOO, Mich., July 29 Stryker Corporation (NYSE: ... Directors to nine and the election of Dr. Srikant M. Datar as ... Associate Dean and Director of Research at the Graduate School of Business ... at Harvard University since joining that organization in 1996. , , ...
... , , , , ... a worldwide leader in the development, distribution and use of ... $5 million financing commitment from Toronto-based MMV Financial ("MMV"). ... on-going cutting-edge clinical research, including immunotherapy and focal therapy, for ...
... ... of being overbilled, double-billed or billed for expenses they didn,t incur. , ... Norwalk, CT (PRWEB) July 29, 2009 -- ccording ... role in fully half of all U.S. foreclosures. CreditFYI, an educational consumer website on ...
... , , NEW YORK, July ... Cristie Kerr in 2003 with a mission to raise funds and ... classic will be held at Liberty National. The event, on Friday, ... a dinner reception and poker tournament. Renowned celebrity chef Todd ...
... North Carolina are reporting assembly of the first functioning ... inside cells helps process and package hormones, enzymes, and ... The lab-on-a-chip device could lead to a faster and ... or blood thinner, the researchers note. Their study is ...
Cached Medicine News:Health News:Stryker Announces Election of New Director 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 3Health News:As Medical Bills Contribute to 50% of U.S. Foreclosures, CreditFYI Shares 5 Tactics for Managing Medical Debt 2Health News:Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Women's Golfer, Cristie Kerr 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Round serrated handle, dull finish....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Medicine Products: